- cafead Jun 03, 2022 at 11:02: AM
via As Boehringer Ingelheim looks to build out its efforts in oncology, its latest deal will turn toward Singapore.
The German pharma announced Thursday that it has signed a global licensing agreement with the Singapore-based Agency for Science, Technology and Research (A*STAR). While specific financial breakdown was not disclosed, Boehringer will pay more than €100 million ($107 million) in upfront cash and milestones, as well as success-based development and commercialization targets.
article source
The German pharma announced Thursday that it has signed a global licensing agreement with the Singapore-based Agency for Science, Technology and Research (A*STAR). While specific financial breakdown was not disclosed, Boehringer will pay more than €100 million ($107 million) in upfront cash and milestones, as well as success-based development and commercialization targets.
article source